We fund and support clinical trials which seek to slow, stop or reverse Parkinson’s. Find out about the trials which are recruiting as part of our International Linked Clinical Trials (iLCT) programme developed in partnership with Van Andel Institute.

Please note: The current pandemic has slowed, and in some cases stopped, the recruitment process to these clinical studies. Each site will have guidelines and advice about their own COVID protocols.

The ADepT-PD trial (nortriptyline)

This trial is recruiting 408 people in 30 centres across the UK. Funded by the NIHR with support from Cure Parkinson’s, the trial lead is Professor Anette Schrag, the Royal Free Hospital, London. Cure Parkinson’s is supporting a sub-study of this trial which will be…

The Bydureon (exenatide) phase 3 trial

Cure Parkinson’s is delighted to be supporting two sub-studies within the Bydureon phase 3 trial which has begun recruiting from six sites in the UK. This phase 3 efficacy trial in a larger cohort is the next stage in a programme of trials and research…

News Research news
PD Frontline

As research has expanded in the area of Parkinson’s genetics, researchers have been able to uncover a number of genes which have been linked to an increased risk of developing Parkinson’s. About 10% of Parkinson’s diagnoses are linked to a genetic cause. Researchers believe that…